Rachel Laing joined Bionest in 2010, working in the NY office for 5 years, and recently relocating to Basel, Switzerland, where she splits her time between the New York and Paris offices.
Her areas of medical expertise include oncology and immuno-oncology, neurology, orphan diseases, and autoimmune. Dr. Laing has advised numerous clients on topics such as opportunity assessments, biomarker and CDx strategy, corporate development strategy, strategic planning, and clinical and commercial strategy plans. She has a Ph.D. in Medical and Molecular Pharmacology at the University of California, Los Angeles (UCLA), where her research was focused on PET imaging biomarkers and Adoptive T cell therapy. Rachel also holds an MS in Neuropharmacology from the University of Oxford, and a BS in Molecular and Cell Biology from UCLA.